Acute Respiratory Distress Syndrome (ARDS) Market

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET

Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible. DelveInsight's "Acute Respiratory Distress Syndrome (ARDS) Market" report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

View report: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Acute Respiratory Distress Syndrome (ARDS) Causes and Symptoms

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.

The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

Acute Respiratory Distress Syndrome (ARDS) Epidemiology  

Some key findings:

·         Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017–2030.

·         DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017.

 Download full report on Acute Respiratory Distress Syndrome (ARDS) Market

Acute Respiratory Distress Syndrome (ARDS) Drug Chapters

In order to meet the high unmet need for ARDS treatment regimen, companies across the globe have shifted their focus toward this therapeutic area. The overall dynamics of the ARDS market is anticipated to change in the coming years owing to the expected launch of emerging therapies. Key players in the market of ARDS are Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeptico Forschung und Entwicklung GmbH, and others.

 

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

For ARDS, we have observed that mechanical ventilation, prone positioning, and other supportive pharmacologic treatment regimens will remain the mainstay of the therapeutic market as there is no approved therapy. A modest increase in the market size of these therapies has been witnessed initially, with a consistent decrease thereafter, owing to the increasing demand for targeted therapies to treat ARDS. Among the 7MM countries, the United States accounts for the highest market size of ARDS in comparison to EU5 and Japan.

According to DelveInsight, Acute Respiratory Distress Syndrome (ARDS) market in 7MM is expected to change in the study period 2017-2030.

Request for sample pages: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Acute Respiratory Distress Syndrome (ARDS) Key Companies

                         

Visit DelveInsight’s repot store to browse through insightful market reports.

 

 


Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more